PHARMACY

Impax Labs acquires two generic drugs

BY Alaric DeArment

HAYWARD, Calif. Generic drug maker Impax Labs has bought the rights to two generic drugs from Watson Pharmaceuticals and Arrow Group, which Watson recently acquired.

Impax announced that it had acquired from Watson the rights to cabergoline, a generic version of Pfizer’s Dostinex, and the pending approval application for dronabinol, a generic version of Unimed’s Marinol, from Cobalt Pharmaceuticals, a subsidiary of Arrow Group.

“Our growth initiatives include evaluating the potential to expand beyond solid oral dosage forms as well as into markets beyond our current U.S. footprint,” Impax president and CEO Larry Hsu said in a statement. “In addition, we will be open to opportunities to in-license products, as well as potential product or company acquisitions that will drive long-term profitable growth.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Careworks wins Web site design award

BY Allison Cerra

DANVILLE, Pa. Careworks Convenient Healthcare received an Honor of Distinction for Best Site Design at the eHealthcare Leadership Awards for its Web site, www.careworkshealth.com/geisinger. Award winners were recognized during a special presentation at the 13th annual Healthcare Internet Conference Nov. 2 to 4 in Las Vegas.

The eHealthcare Leadership Award for Best Site Design recognizes unique, attractive and engaging Web designs that facilitate access to key site information and provide strong branding and excellent usability. Careworks’ site was selected from more than 1,100 entries.

“We are pleased that the Careworks Web site was recognized for its distinctive and engaging design,” said Dean Lin, CEO of Careworks and VP business development at Geisinger Health System. “As a health system operating retail clinics, we wanted a thoughtful, consumer-friendly design that provided us with unique branding opportunities.”

The eHealthcare Leadership Awards program was developed and first presented 10 years ago by eHealthcare Strategy & Trends, a leading Internet resource published by Health Care Communications, Rye, N.Y.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

FDA approves Novo Nordisk’s atrophic vaginitis treatment

BY Alaric DeArment

PRINCETON, N.J. The Food and Drug Administration has approved a 10-microgram formulation of a suppository for treating atrophic vaginitis.

Danish drug maker Novo Nordisk announced Wednesday the approval of Vagifem (estradiol), saying that the 10 microgram formulation makes it the lowest local estrogen therapy dose commercially available in the United States. The drug will reach pharmacy shelves during first quarter 2010, the company said.

Atrophic vaginitis affects up to 75% of postmenopausal women, causing thinning and shrinking of vaginal tissues that leads to dryness, soreness and irritation.

The 25 microgram formulation was approved in the United States in 1999.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES